Omnipod Insulin Pump Working Well For Insulet, Lifts Annual Forecast
Portfolio Pulse from Vandana Singh
Insulet Corporation (NASDAQ:PODD) reported Q3 sales of $432.7 million, up 27.0%, beating the consensus of $414.383 million. The company also reported an adjusted EPS of $0.71, beating the consensus of $0.40. Insulet raised its FY23 revenue growth forecast to 26%-27% and expects total Omnipod growth between 29% and 30%. The company also received FDA clearance for the Omnipod 5 app on Apple iOS and plans to integrate Omnipod 5 with the Dexcom G7 by early 2024.
November 03, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Insulet Corporation reported strong Q3 results, beating consensus estimates for sales and EPS. The company also raised its FY23 revenue growth forecast and received FDA clearance for the Omnipod 5 app on Apple iOS.
Insulet Corporation's strong Q3 results and raised FY23 forecast indicate a positive outlook for the company. The FDA clearance for the Omnipod 5 app also opens up new opportunities for growth. These factors are likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100